What happened
Shares of Cassava Sciences (NASDAQ: SAVA), a clinical-stage biopharmaceutical company, plunged Wednesday after The Wall Street Journal published an article reporting that the Securities and Exchange Commission is investigating allegations about the company that surfaced earlier this year. As of 1:04 p.m. ET, the stock was down by 22.1%.
So what
In the quarterly report it filed with the SEC on Monday, Cassava Sciences disclosed that it had received information requests from certain government agencies. The company didn't elaborate about which agencies were making requests, nor did it say what information they asked for.
Image source: Getty Images.
But on Wednesday morning, The Wall Street Journal reported -- crediting sources familiar with the matter -- that the SEC is investigating claims that Cassava manipulated research results.
Now what
The drug candidate, simufilam, is supposed to improve the function of a protein called filamin A and thereby prevent the progression of Alzheimer's disease. It's the first new drug candidate that targets filamin A to begin a phase 3 trial. Until the results read out, investors can expect this stock to be very susceptible to skepticism.
Earlier this month, a review conducted by The Journal of Neuroscience found no evidence of data manipulation in a key research paper supporting simufilam as a treatment for Alzheimer's disease.
On Monday, Cassava Sciences told investors to expect significantly higher operating expenses in the fourth quarter and further out. The company anticipates increased legal and professional fees related to ongoing securities class action lawsuits and governmental investigations.
10 stocks we like better than Cassava Sciences, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Cassava Sciences, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of November 10, 2021
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
